Overview

* Evolus Q3 2025 revenue rises 13% yr/yr, driven by Jeuveau and Evolysse growth

* Company expects positive non-GAAP operating income in Q4 2025

* Evolus ( EOLS ) reaffirms 2025 revenue guidance of $295 mln to $305 mln

Outlook

* Evolus ( EOLS ) reaffirms 2025 net revenue guidance of $295 mln to $305 mln

* Company expects positive non-GAAP operating income of $5 mln to $7 mln in Q4 2025

* Evolus ( EOLS ) plans U.S. launch of Evolysse™ Sculpt in 2026 and Evolysse™ Lips in 2027

Result Drivers

* JEUVEAU GROWTH - Sequential growth in Jeuveau revenue outperformed typical seasonal trends

* EVOLYSSE LAUNCH - Evolysse delivered $5.7 mln in revenue, marking the strongest HA filler debut in over a decade

* EXPENSE MANAGEMENT - Strategic mid-year expense reductions lowered operating costs, strengthening financial position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $68.97

Product mln

Revenue

Q3 Net -$15.74

Income mln

Q3 Gross 66.50%

Margin

Q3 67.60%

Adjusted

Gross

Margin

Q3 Gross $45.84

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Evolus Inc ( EOLS ) is $19.50, about 67.1% above its November 4 closing price of $6.41

* The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)